Summary
Our prior in vitro studies on the correction of multidrug resistance by cyclosporin A (CsA) prompted us to investigate the effect of CsA and VP-16 in vivo. CsA given simultaneously at 2 or 10 mg/kg with VP-16 to BDF/1 mice bearing parental drug-sensitive P388 or L1210 lymphatic leukemia produced a 100% increase in survival as compared with VP-16 treatment alone. CsA-containing regimens also promoted 60-day survival in a significant number of P388 or L1210 leukemia-bearing mice as compared with animals receiving VP-16 in the absence of CsA (P<0.02 andP<0.001, respectively). CsA enhancement of the survival of mice bearing these lymphatic leukemias is restricted to VP-16, since the addition of CsA to therapeutic agents such as vincristine, daunorubicin, methotrexate, or cisplatin had no effect on survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Canafax DM, Ascher NL (1983) Cyclosporin immunosuppression. Clin Pharmacy 2:515–524
Cho J, Hurtado N, Wong S, Armentrout S, Meyskens F, White C, Osann K, Slater L (1991) Phase I–II trial of cyclosporin A (CsA), cisplatinum (CDDP) and VP-16 in non-small cell lung cancer (NSCLC). Proc of ASCO 10
Driscoll JS (1984) The preclinical new drug research program of the National Cancer Institute. Cancer Treat Rep 68:63–75
Issell BF, Muggia FM Carter SK (1984) Etoposide (VP-16) Current Status and New Developments. Academic Press, Orlando
Meador J, Sweet P, Stupecky M, Wetzel M, Murray S, Gupta S, Slater L (1987) Enhancement of cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Meth 65:55–63
Osieka R, Seeber S, Pannenbacker R, Soll D, Glatte P, Schmidt CG (1986) Enhancement of etoposide-induced cytotoxicity by cyclosporin A. Cancer Chemother Pharmacol 18:198–202
Slater LM, Murray SL, Wetzel MW, Sweet P Stupecky M (1986) Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol 16:50–54
Slater LM, Sweet P, Stupecky M, Gupta S (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77:1405–1408
Slater LM, Sweet P, Stupecky M, Wetzel MW, Gupta S (1986) Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235–238
Slater LM, Wetzel MW, Cesario T (1981) Combined interferon-antimetabolite therapy of murine L1210 leukemia. Cancer 48:5–9
Venditti JM (1981) Preclinical drug development: rationale and methods. Semin Oncol 8:349–361
Yahanda AM, Adler KM, Hardy R, Brophy NA, Halsey J, Sikic BI (1991) A phase I trial of etoposide (E) with cyclosporine (CsA) as a modulator of multidrug resistance (MDR). Proc of ASCO 10
Author information
Authors and Affiliations
Additional information
This study was supported by the Marcia Slater Society for Research in Leukemia, the Jacob Wallerstein Foundation, and the Children's Leukemia Research Foundation
Rights and permissions
About this article
Cite this article
Slater, L.M., Cho, J. & Wetzel, M. Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother. Pharmacol. 31, 53–56 (1992). https://doi.org/10.1007/BF00695994
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00695994